Adipose tissue-derived lipokines in metabolism.
Journal
Current opinion in genetics & development
ISSN: 1879-0380
Titre abrégé: Curr Opin Genet Dev
Pays: England
ID NLM: 9111375
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
received:
20
03
2023
revised:
21
06
2023
accepted:
22
06
2023
pmc-release:
01
08
2024
medline:
15
8
2023
pubmed:
21
7
2023
entrez:
20
7
2023
Statut:
ppublish
Résumé
Adipose tissue is a crucial regulator of metabolism with functions that include energy storage and dissipation as well as the secretion of bioactive molecules. As the largest endocrine organ in the body, the adipose tissue produces diverse bioactive molecules, including peptides, metabolites, and extracellular vesicles, which communicate with and modulate the function of other organs. In recent years, lipid metabolites, also known as lipokines, have emerged as key signaling molecules that actively participate in multiple metabolic processes. This review highlights the latest advances in adipose tissue-derived lipokines and their underlying cellular and molecular functions. Furthermore, we offer our perspective on the future directions for adipose-derived bioactive lipids and potential therapeutic implications for obesity and its associated complications.
Identifiants
pubmed: 37473635
pii: S0959-437X(23)00069-2
doi: 10.1016/j.gde.2023.102089
pmc: PMC10528474
mid: NIHMS1914289
pii:
doi:
Types de publication
Journal Article
Review
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
102089Subventions
Organisme : American Heart Association-American Stroke Association
ID : 903968
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK036836
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK102898
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK122808
Pays : United States
Informations de copyright
Copyright © 2023 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest Y.-H.T. is an inventor of a US patent on 12,13-dihydroxy-9Z-octadecenoic acid and metabolic diseases and a pending provisional patent application related to maresin 2 and metabolic therapeutics.
Références
J Clin Endocrinol Metab. 2020 Jul 1;105(7):
pubmed: 32343312
N Engl J Med. 2022 Feb 24;386(8):768-779
pubmed: 35196429
Nutrients. 2019 Oct 11;11(10):
pubmed: 31614481
J Cell Physiol. 2017 Nov;232(11):2923-2928
pubmed: 28191637
J Nutr Biochem. 2020 May;79:108361
pubmed: 32179409
Nature. 2022 Jun;606(7916):968-975
pubmed: 35676490
Biochim Biophys Acta Mol Cell Biol Lipids. 2020 May;1865(5):158639
pubmed: 31988049
Proc Natl Acad Sci U S A. 2021 Jan 12;118(2):
pubmed: 33372146
Cell Metab. 2018 May 01;27(5):1111-1120.e3
pubmed: 29719226
Nat Med. 2017 May;23(5):631-637
pubmed: 28346411
Cell. 2008 Sep 19;134(6):933-44
pubmed: 18805087
Pharmacol Ther. 2021 Nov;227:107879
pubmed: 33915177
Nat Rev Immunol. 2015 Aug;15(8):511-23
pubmed: 26139350
FASEB J. 2021 Apr;35(4):e21354
pubmed: 33749892
Mol Nutr Food Res. 2020 Jun;64(11):e1901238
pubmed: 32277573
Nat Commun. 2020 Mar 17;11(1):1421
pubmed: 32184391
Cell. 2014 Oct 9;159(2):318-32
pubmed: 25303528
Cell Metab. 2018 Feb 6;27(2):419-427.e4
pubmed: 29414687
Front Immunol. 2018 Jan 29;9:38
pubmed: 29434586
Prostaglandins Leukot Essent Fatty Acids. 2022 Nov;186:102508
pubmed: 36270150
J Lipid Res. 2021;62:100108
pubmed: 34418413
Mol Aspects Med. 2020 Aug;74:100894
pubmed: 32893032
Nat Rev Endocrinol. 2021 Dec;17(12):726-744
pubmed: 34625737
Mol Aspects Med. 2019 Aug;68:101-107
pubmed: 30965049
Rev Endocr Metab Disord. 2022 Feb;23(1):1-4
pubmed: 35048260
Diabetologia. 2020 Jan;63(1):206-218
pubmed: 31676981
Curr Opin Pharmacol. 2020 Jun;52:1-8
pubmed: 32387807
Am J Cardiovasc Dis. 2021 Aug 15;11(4):504-529
pubmed: 34548951
Eur J Pharmacol. 2017 Feb 5;796:7-19
pubmed: 27940058
Circ Res. 2022 Jul 8;131(2):168-183
pubmed: 35642564
Lab Chip. 2018 Sep 11;18(18):2873-2882
pubmed: 30109329
Mol Immunol. 2022 Jun;146:78-86
pubmed: 35462079
Biochim Biophys Acta Mol Cell Biol Lipids. 2020 Oct;1865(10):158776
pubmed: 32738301
Ann N Y Acad Sci. 2022 May;1511(1):87-106
pubmed: 35218041
Circulation. 2021 Jan 12;143(2):145-159
pubmed: 33106031
Nat Rev Endocrinol. 2019 Sep;15(9):507-524
pubmed: 31296970
Diabetes. 2020 Mar;69(3):300-312
pubmed: 31806624
Cell Metab. 2019 Oct 1;30(4):768-783.e7
pubmed: 31353262
Diabetologia. 2019 Nov;62(11):2079-2087
pubmed: 31309263
FASEB J. 2021 Jun;35(6):e21592
pubmed: 33960028
Endocrinology. 2019 Oct 1;160(10):2314-2325
pubmed: 31504387
Nat Metab. 2022 Jun;4(6):775-790
pubmed: 35760872
J Clin Invest. 2018 Jul 2;128(7):2657-2669
pubmed: 29757195
Diabetologia. 2013 Jun;56(6):1394-402
pubmed: 23508306
Rev Endocr Metab Disord. 2022 Feb;23(1):31-41
pubmed: 33712997
JCI Insight. 2022 Mar 8;7(5):
pubmed: 35260536
Neuropharmacology. 2022 Sep 15;216:109189
pubmed: 35820471
Adipocyte. 2021 Dec;10(1):48-65
pubmed: 33403891
FASEB J. 2021 May;35(5):e21572
pubmed: 33826782
Cell Metab. 2012 Aug 8;16(2):189-201
pubmed: 22863804
Diabetes. 2020 Dec;69(12):2541-2548
pubmed: 33219098
Cells. 2022 Jun 02;11(11):
pubmed: 35681514
PLoS One. 2014 Jul 18;9(7):e102362
pubmed: 25036362
J Clin Invest. 2019 Oct 1;129(10):4138-4150
pubmed: 31449056
Lancet. 2017 Dec 16;390(10113):2627-2642
pubmed: 29029897
Sci Rep. 2021 May 17;11(1):10426
pubmed: 34001916
J Clin Endocrinol Metab. 2021 Jan 23;106(2):e943-e956
pubmed: 33135728
J Clin Endocrinol Metab. 2021 Mar 8;106(3):e1458-e1459
pubmed: 33289023
Diabetes. 2016 Jul;65(7):1800-7
pubmed: 27288005